Liquidia Corporation Common Stock vs Main Street Capital Corporation — how do they compare? Liquidia Corporation Common Stock trades at $33.46 (market cap $2.40B), while Main Street Capital Corporation trades at $53.66 (market cap $5.03B). The key difference: Main Street Capital Corporation is far larger — about 2.1× Liquidia Corporation Common Stock's market cap, and Main Street Capital Corporation pays a 5.91% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Main Street Capital Corporation for 89 Days on average.
| LQDA | MAIN | |
|---|---|---|
Market Cap | $2.40B | $5.03B |
Volume | 2,857,547 | 386,945 |
Sector | Health | Financials |
52-Week High | $91.03 | $64.60 |
52-Week Low | $22.02 | $49.63 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $2.30B | $7.48B |
Dividend Yield | — | 5.91% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MAIN trades at $53.50, down 0.3% on the day, with a bearish technical signal and key support at $53. The stock shows strong profitability with an 80.77% net margin and a P/E of 10.8, but revenue declined slightly in 2025 to $592M. Recent quarterly earnings have been mixed, beating in Q2 2026 but missing in Q1. The company maintains a consistent dividend, with recent payments of $0.27-$0.30 per share.
The outlook is cautious; while MAIN's high margins and dividend yield near 7.9% appeal to income investors, bearish technicals, softening revenue, and a high proportion of analyst 'Hold' ratings suggest limited near-term upside. Risks include earnings volatility and sensitivity to interest rates, but the stock trades below the consensus price target of $58, offering potential appreciation if fundamentals stabilize.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →